BeiGene opens biologics facility in New Jersey, US
BeiGene has announced the opening of its new US biologics manufacturing and clinical research and development (R&D) facility at Hopewell, New Jersey. Situated at the Princeton West Innovation Campus, the site is set to play a crucial role in providing innovative medicines to cancer patients worldwide.
Dedicated to commercial-stage biologic pharmaceutical manufacturing, the new facility spans 42 acres and is designed with the flexibility to scale production to meet current and future demands. BeiGene investment of $800m in the facility is the result of a three-year project aimed at enhancing its manufacturing and R&D capabilities in the US.
By the end of 2025, the site is expected to generate hundreds of high-tech employment opportunities. BeiGene currently has more than 30 molecules at various stages of clinical and commercial development. Its oncology pipeline includes new treatments such as targeted degraders, antibody-drug conjugates, monoclonal antibodies and traditional small molecules.
These therapies have the potential to combat 80% of the world’s cancers.
BeiGene’s latest expansion enhances its research and clinical development capabilities and ensures production scalability.
The strategic move is aimed at lowering costs, bolstering supply chain resilience, mitigating the impact of global disruptions, safeguarding production capacity and swiftly adapting to new innovative modalities.
In March 2024, the US Food and Drug Administration (FDA) approved BeiGene’s TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or metastatic oesophageal squamous cell carcinoma after previous systemic chemotherapy.
July 26, 2024
